ATE376559T1 - Methoden der verhinderung und behandlung der alzheimer'schen krankheit - Google Patents
Methoden der verhinderung und behandlung der alzheimer'schen krankheitInfo
- Publication number
- ATE376559T1 ATE376559T1 AT05107898T AT05107898T ATE376559T1 AT E376559 T1 ATE376559 T1 AT E376559T1 AT 05107898 T AT05107898 T AT 05107898T AT 05107898 T AT05107898 T AT 05107898T AT E376559 T1 ATE376559 T1 AT E376559T1
- Authority
- AT
- Austria
- Prior art keywords
- arg
- glu
- asp
- tyr
- phe
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 5
- 230000002265 prevention Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- RBXSZQRSEGYDFG-GUBZILKMSA-N Glu-Lys-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O RBXSZQRSEGYDFG-GUBZILKMSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000001777 nootropic effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT362003 | 2003-01-14 | ||
| AT0146403A AT413945B (de) | 2003-01-14 | 2003-09-17 | Impfstoff für die alzheimer-krankheit |
| PCT/EP2004/000162 WO2004062556A2 (en) | 2003-01-14 | 2004-01-13 | Methods for preventing and treating alzheimer’s disease (ad) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE376559T1 true ATE376559T1 (de) | 2007-11-15 |
Family
ID=32714004
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT0146403A AT413945B (de) | 2003-01-14 | 2003-09-17 | Impfstoff für die alzheimer-krankheit |
| AT05107898T ATE376559T1 (de) | 2003-01-14 | 2004-01-13 | Methoden der verhinderung und behandlung der alzheimer'schen krankheit |
| AT04701585T ATE458753T1 (de) | 2003-01-14 | 2004-01-13 | Methoden der verhinderung und behandlung der alzheimer'schen krankheit |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT0146403A AT413945B (de) | 2003-01-14 | 2003-09-17 | Impfstoff für die alzheimer-krankheit |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04701585T ATE458753T1 (de) | 2003-01-14 | 2004-01-13 | Methoden der verhinderung und behandlung der alzheimer'schen krankheit |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7732568B2 (de) |
| EP (2) | EP1679319B1 (de) |
| JP (2) | JP4547373B2 (de) |
| CN (2) | CN102526699A (de) |
| AT (3) | AT413945B (de) |
| CA (1) | CA2513218C (de) |
| CY (2) | CY1107146T1 (de) |
| DE (2) | DE602004025668D1 (de) |
| DK (2) | DK1583774T3 (de) |
| ES (2) | ES2296084T3 (de) |
| PL (1) | PL209989B1 (de) |
| PT (2) | PT1583774E (de) |
| SI (1) | SI1583774T1 (de) |
| WO (1) | WO2004062556A2 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004056318A2 (en) | 2002-12-19 | 2004-07-08 | New York University | Method for treating amyloid disease |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| AT413336B (de) * | 2003-09-12 | 2006-02-15 | Mattner Frank Dr | Apherese-vorrichtung |
| WO2005072777A2 (en) * | 2004-01-28 | 2005-08-11 | Curix Aps | Conjugates of amyloid proteins as vaccines for amyloid-related diseases |
| AT413946B (de) * | 2004-07-13 | 2006-07-15 | Mattner Frank Dr | Impfstoff gegen die alzheimer-krankheit |
| AT500483B1 (de) * | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
| CA2628703C (en) | 2005-11-30 | 2019-10-29 | Abbott Laboratories | Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
| DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
| MX358175B (es) | 2005-12-12 | 2018-08-08 | Ac Immune Sa | Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas. |
| EP1878747A1 (de) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-hergestellte Antikörper |
| PL2468770T3 (pl) | 2006-07-14 | 2018-07-31 | Ac Immune S.A. | Humanizowane przeciwciało przeciw amyloidowi beta |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| TWI557136B (zh) * | 2007-06-12 | 2016-11-11 | Ａｃ免疫公司 | 特異性結合β-類澱粉蛋白之抗體及相關核酸分子、表現載體、細胞、組合物、套組、方法及用途 |
| US8613923B2 (en) * | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| AU2008311366B2 (en) * | 2007-10-05 | 2015-03-12 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| WO2009048537A2 (en) * | 2007-10-05 | 2009-04-16 | Genentech, Inc. | Humanized antibody |
| DK2238166T3 (da) * | 2007-10-05 | 2014-01-27 | Ac Immune Sa | Anvendelse af et anti-amyloid-beta-antistof ved øjensygdomme |
| EP2226081A4 (de) | 2007-10-25 | 2011-10-12 | Univ Kagoshima | Peptid-vakzine mit einem mimic-molekül von amyloid-peptid |
| CN104098695B (zh) * | 2007-10-29 | 2018-09-07 | 道健康生活医药株式会社 | 抗体及其应用 |
| EP2278998A1 (de) | 2008-04-17 | 2011-02-02 | Declion Pharmaceuticals, Inc. | Entwurf und synthese von polymerzusammensetzungen mit gezielter sequenz und antikörper davon zur behandlung von proteinkonformationsstörungen |
| AT506819B1 (de) * | 2008-06-12 | 2011-06-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzin zur behandlung von alzheimer-krankheit |
| KR20110036809A (ko) * | 2008-06-12 | 2011-04-11 | 아피리스 아게 | 파킨슨병과 관련된 증상을 치료하기 위한 화합물 |
| AT506820B1 (de) * | 2008-06-12 | 2011-07-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzine gegen alzheimer-krankheit |
| CN104744591B (zh) | 2010-04-15 | 2022-09-27 | Abbvie德国有限责任两合公司 | β淀粉样蛋白结合蛋白 |
| AU2011282536B2 (en) | 2010-07-30 | 2015-12-24 | Ac Immune S.A. | Safe and functional humanized anti beta-amyloid antibody |
| WO2012024187A1 (en) | 2010-08-14 | 2012-02-23 | Abbott Laboratories | Amyloid-beta binding proteins |
| US20120328605A1 (en) * | 2010-10-27 | 2012-12-27 | Daniel Larocque | Compositions and uses |
| GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| ES2496341T3 (es) | 2011-10-04 | 2014-09-18 | Affiris Ag | Procedimiento para detectar anticuerpos Aß-específicos en una muestra biológica |
| EP2787347A1 (de) | 2013-04-03 | 2014-10-08 | Affiris AG | Verfahren zur Erkennung von Aß-spezifischen Antikörpern in einer biologischen Probe |
| US10381614B2 (en) * | 2013-04-17 | 2019-08-13 | Samsung Sdi Co., Ltd. | Battery module |
| WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| RU2734924C2 (ru) | 2015-11-03 | 2020-10-26 | Аффирис Аг | Способ вакцинации против аутоантигена у пациента-человека |
| CN105237628B (zh) * | 2015-11-17 | 2018-08-07 | 南开大学 | 一种用于治疗阿尔兹海默症的多肽 |
| CN107022019B (zh) * | 2016-11-24 | 2020-10-30 | 桂林医学院 | 一种用于脑内降铁除自由基的多肽、制备方法与应用 |
| WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| EP3918323A4 (de) | 2019-01-30 | 2022-12-28 | TrueBinding, Inc. | Anti-gal3-antikörper und verwendungen davon |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| AU2023223603A1 (en) | 2022-02-28 | 2024-08-22 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN. |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK590288D0 (da) * | 1988-10-24 | 1988-10-24 | Symbicom Ab | Kemiske forbindelser |
| US5650489A (en) * | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| GB9022190D0 (en) * | 1990-10-12 | 1990-11-28 | Perham Richard N | Immunogenic material |
| US5639603A (en) * | 1991-09-18 | 1997-06-17 | Affymax Technologies N.V. | Synthesizing and screening molecular diversity |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6088993A (en) | 1999-02-05 | 2000-07-18 | Irace; Francisco D. | Closure system |
| CA2363118A1 (en) | 1999-02-25 | 2000-08-31 | Smithkline Beecham Biologicals S.A. | Immunogens comprising a peptide and a carrier derived from h.influenzae protein d |
| US6703491B1 (en) * | 1999-03-17 | 2004-03-09 | Exelixis, Inc. | Drosophila sequences |
| CA2349434A1 (en) * | 1999-09-03 | 2001-03-15 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
| CZ20022971A3 (cs) | 2000-03-03 | 2003-02-12 | Smithkline Beecham Biologicals S. A. | Vakcinační prostředek vhodný pro léčbu aterosklerózy |
| GB0024200D0 (en) * | 2000-10-03 | 2000-11-15 | Smithkline Beecham Sa | Component vaccine |
| DE50111493D1 (de) | 2001-09-03 | 2007-01-04 | Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh | Antigen-Mimotope und Vakzine gegen Krebserkrankungen |
| DK1361439T3 (da) * | 2002-05-07 | 2007-03-26 | Pasteur Institut | Screening for peptider, der hæmmer PP1c-binding til Bcl-2, Bcl-xl- og Bcl-w-proteiner |
-
2003
- 2003-09-17 AT AT0146403A patent/AT413945B/de not_active IP Right Cessation
-
2004
- 2004-01-13 PT PT04701585T patent/PT1583774E/pt unknown
- 2004-01-13 ES ES05107898T patent/ES2296084T3/es not_active Expired - Lifetime
- 2004-01-13 DE DE602004025668T patent/DE602004025668D1/de not_active Expired - Lifetime
- 2004-01-13 DK DK04701585.4T patent/DK1583774T3/da active
- 2004-01-13 EP EP05107898A patent/EP1679319B1/de not_active Expired - Lifetime
- 2004-01-13 PL PL378333A patent/PL209989B1/pl unknown
- 2004-01-13 CN CN2011103110387A patent/CN102526699A/zh active Pending
- 2004-01-13 CN CN200480002213.2A patent/CN1826354B/zh not_active Expired - Fee Related
- 2004-01-13 AT AT05107898T patent/ATE376559T1/de active
- 2004-01-13 WO PCT/EP2004/000162 patent/WO2004062556A2/en not_active Ceased
- 2004-01-13 US US10/540,551 patent/US7732568B2/en not_active Expired - Fee Related
- 2004-01-13 DE DE602004009705T patent/DE602004009705T2/de not_active Expired - Lifetime
- 2004-01-13 CA CA2513218A patent/CA2513218C/en not_active Expired - Fee Related
- 2004-01-13 SI SI200431399T patent/SI1583774T1/sl unknown
- 2004-01-13 EP EP04701585A patent/EP1583774B1/de not_active Expired - Lifetime
- 2004-01-13 JP JP2006500553A patent/JP4547373B2/ja not_active Expired - Fee Related
- 2004-01-13 DK DK05107898T patent/DK1679319T3/da active
- 2004-01-13 AT AT04701585T patent/ATE458753T1/de active
- 2004-01-13 PT PT05107898T patent/PT1679319E/pt unknown
- 2004-01-13 ES ES04701585T patent/ES2339447T3/es not_active Expired - Lifetime
-
2008
- 2008-01-17 CY CY20081100069T patent/CY1107146T1/el unknown
-
2010
- 2010-03-08 JP JP2010051012A patent/JP5282058B2/ja not_active Expired - Fee Related
- 2010-04-01 US US12/752,451 patent/US20110015131A1/en not_active Abandoned
- 2010-05-07 CY CY20101100399T patent/CY1110634T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE376559T1 (de) | Methoden der verhinderung und behandlung der alzheimer'schen krankheit | |
| TW200602071A (en) | Methods for preventing and treating alzheimer's disease (ad) | |
| AT500379B1 (de) | Tau-proteine | |
| NO20045021L (no) | Immunologiske metoder og preparater for behandling av Alzheimers sykdom | |
| DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
| ATE283289T1 (de) | Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten | |
| NO20022531L (no) | Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer | |
| BRPI0513959A (pt) | anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos | |
| AU2002302255A1 (en) | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases | |
| EA200702093A1 (ru) | Антитела-миметики glp-1 человека, композиции, способы и их применение | |
| NO20076021L (no) | Antistoffer rettet mot amyloid-betapeptid og metoder som anvender de samme | |
| SE0103754L (sv) | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid | |
| BR0211296A (pt) | Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado | |
| WO2004006952A3 (en) | Therapeutic tuberculosis vaccines | |
| WO2001068708A3 (en) | Human and humanized fap-alpha-specific antibodies | |
| DE60313437D1 (de) | Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4 | |
| ATE512981T1 (de) | Identifizierung von ses-3 (spr-5) aus c. elegans sowie dessen verwendungen | |
| WO2007030771A3 (en) | Targeted identification of immunogenic peptides | |
| ATE338063T1 (de) | Diagnostische verwendungen des t-zell proteins tzon7, der davon abgeleiteten peptide und des antikörpers | |
| DK1569961T3 (da) | Splice variant af det menneskelige hypofysevæksthormon | |
| DE50210281D1 (de) | Identifizierung von ses-1 aus c. elegans sowie dessen verwendung | |
| ATE349532T1 (de) | Zytotoxisches t-zellepitop des papillomavirus l1- proteins und seine verwendung in diagnostik und therapie | |
| WO2007023189A3 (en) | Pharmaceutical composition and its use for the prophylactic or therapeutic treatment of retroviral diseases | |
| WO2002008393A3 (en) | Serine protease from yersinia enterocolitica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEIH | Change in the person of patent owner |